LC/MS/MS法测定血浆中左羟丙哌嗪浓度及其药代动力学

目的建立测定血浆中左羟丙哌嗪的液相色谱-串联质谱法，考察左羟丙哌嗪在中国健康志愿者体内的药代动力学行为。方法血浆样品经液-液提取后，进行色谱分离，在三重四极杆串联质谱仪上，以多重反应离子监测(MRM)方式进行定量分析，用于监测的离子为m/z 237 → m/z 120（左羟丙哌嗪）和m/z 288 → m/z 58(佐米曲普坦，内标)。结果左羟丙哌嗪的最低定量浓度为0.25 μg·L^-1，线性范围为0.25-500.0 μg·L^-1，精密度与准确度符合生物样品分析要求。结论该法操作简便、快速、灵敏度高。可检测出健康志愿者po左羟丙哌嗪60 mg,其24 h后的血药浓度，适于临床药代动力学研究。

Determination of levodropropizine and its pharmacokinetics in human plasma using LC/MS/MS

AIM: To develop a rapid and sensitive LC/MS/MS method for the analysis of levodropropizine in plasma and study the pharmacokinetics of levodropropizine in healthy Chinese volunteers. METHODS: Levodropropizine and zolmitriptan (internal standard, IS) were extracted from plasma samples and chromatographed on a C18 column and detected using a tandem mass spectrometer with a TurboIon Spray ionization interface. Quantitation was performed using multiple reaction monitoring (MRM) of the transitions of the m/z 237 --> m/z 120 for levodropropizine and m/z 288 --> m/z 58 for the IS. RESULTS: The limit of quantification of the method for levodropropizine was 0.25 microg x L(-1). The assay was linear over the concentration range from 0.25 to 500.0 microg x L(-1) and intra- and inter-day precision over this range were < 11.4% with good accuracy. CONCLUSION: The method is shown to be accurate, and suitable for clinical pharmacokinetic study of levodropropizine.